drugset
drugset / Trial / NCT04985669

Study of Comparative Effectiveness of Prucalopride and Lubiprostone in Constipation Predominant Irritable Bowel Syndrome

NCT04985669 ↗

Phase 4 Unknown 140 enrolled Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
Non-randomizedParallel-groupOpen-labelOther

Summary

This will be a semi-experimental study on constipation predominant IBS patient. One group of patient will receive prucalopride 2mg daily and another group of patient will receive lubiprostone 8 microgram twice daily. IBS-SSS and IBS-QOL score will be recorded at baseline and at follow up at 3 week and 6 week. Effectiveness of both drug will be evaluated by comparing the baseline data with data at 3 week and 6 week(IBS-SSS and IBS-QOL).

Timeline

Start
2021-08-15
Primary completion
2022-02
Completion
2022-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Lubiprostone Small molecule 8 ug —
Subject Prucalopride Small molecule 2 mg —

Indications

No indication recorded.